India, May 8 -- Traws Pharma Inc. (TRAW), a clinical-stage biopharmaceutical company, on Friday announced plans to advance potential clinical candidates for the treatment and prevention of Hantavirus infections.
Following the announcement, shares are up over 20% in the pre-market.
Traws specializes in the manufacture of small-molecule antiviral drugs targeting negative-strand RNA viruses, such as influenza, H5N1 bird flu, and SARS CoV-2. RNA viruses face obstacles in replicating their genomes during pathogenesis in eukaryotic cells, allowing for the small molecule antivirals to effectively target the viral bodies with high specificity and safety.
Hantaviruses are a group of negative-strand RNA viruses, commonly borne and transmitted by r...